Brief: Shield Therapeutics Says Accrufer Receives Marketing Authorisation In South Korea
07/11/2025 07:34
Nov 7 (Reuters) - Shield Therapeutics PLC STXS.L: ACCRUFER RECEIVES AUTHORISATION BY KOREAN MINISTRY ELIGIBLE FOR PAYMENTS UPON FIRST SALE AND ROYALTIES ON NET SALES OF ACCRUFER IN SOUTH KOREA ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Shield Therapeutics
See all newsBrief: Shield Therapeutics To Assume Full Commercial Control Of ACCRUFeR In US
Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US
Shield Therapeutics - Interim results for the six months ended 30 Jun 26
Brief: Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO
Shield Therapeutics - Q2 and H1 2026 Trading Update